MP79-08 EFFECT OF HORMONE THERAPY ON SEMEN ANALYSIS PARAMETERS IN ADOLESCENT TRANSGENDER FEMALES

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP79-08 EFFECT OF HORMONE THERAPY ON SEMEN ANALYSIS PARAMETERS IN ADOLESCENT TRANSGENDER FEMALES Sai Allu, Sreeya Komaravolu, Mark Sigman, Gabriella Avellino, and Sarah Moore Sai AlluSai Allu More articles by this author , Sreeya KomaravoluSreeya Komaravolu More articles by this author , Mark SigmanMark Sigman More articles by this author , Gabriella AvellinoGabriella Avellino More articles by this author , and Sarah MooreSarah Moore More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003356.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Feminizing transgender patients represent an important urological patient population with unique healthcare needs. Although not every patient chooses to cryopreserve, everyone should be given the option. Hormone therapy (HT) is often started prior to proceeding with surgical orchiectomy. Research has suggested that transgender females on HT have reduced semen analysis (SA) parameters compared to cisgender patients, including reduced sperm concentration and motility. [1,2] There is limited information regarding fertility preservation by transgender patients on HT. The goal of this study is to report cryopreservation outcomes by adolescent feminizing transgender patients who are currently on HT. METHODS: We retrospectively reviewed charts of donors with our Men’s Health Center for direct donations to the sperm bank between 01/2011 to 07/2022. Inclusion criteria included adolescent age (16–24 years old) and the use of HT within three months of cryopreservation. Patient data collected included patient demographics, type of hormone therapy, and SA parameters. RESULTS: Five transgender patients were found who were on HT within three months prior to their semen cryopreservation and analysis. Their median age was 18 (range 16–22). Three patients were on spironolactone, one patient was on estradiol, and one patient was on a combination of both medications. All four patients on single-medication HT had normal concentration and motility on their semen analysis, as defined by the WHO Laboratory Manual for the Examination and Process of Human Semen (Table 1). Three of four patients on single HT had normal volume. The patient on combination HT demonstrated lowered overall SA parameters. CONCLUSIONS: This is the largest cohort of adolescent feminizing transgender patients on hormone therapy in which fertility preservation has been described. Semen cryopreservation could be a viable method for fertility preservation among this patient population who have already initiated hormonal therapies, specifically spironolactone or estradiol. Patients on single HT appear to have improved semen analysis parameters compared to patients on combination HT. Future studies are needed to further characterize fertility preservation with specific information on duration and dosage of HT, as well as outcomes of cryopreservation. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1144 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sai Allu More articles by this author Sreeya Komaravolu More articles by this author Mark Sigman More articles by this author Gabriella Avellino More articles by this author Sarah Moore More articles by this author Expand All Advertisement PDF downloadLoading ...